Form 4: Lexicon Pharmaceuticals SVP Lisa DeFrancesco Reports Stock Transactions
SEC Form 4 Filing
Lisa DeFrancesco, SVP of Investor Relations and Corporate Communications at Lexicon Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units on February 28, 2025.
Summary
- On February 28, 2025, Lisa DeFrancesco, SVP of Investor Relations and Corporate Communications at Lexicon Pharmaceuticals, reported transactions involving the company's stock.
- These transactions included the acquisition of 24,673 shares of common stock through the vesting of restricted stock units.
- DeFrancesco also disposed of 9,096 shares to cover tax withholding obligations at a price of $0.67 per share.
- Following these transactions, DeFrancesco directly owns 15,577 shares of common stock and 49,347 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which is important for investors to gauge management's sentiment and confidence in the company.
Stakeholder Impact
- The transactions may provide insights to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of stock transactions (acquisition and disposal) and vesting of restricted stock units. |
| 03/03/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, LXRX, Lexicon Pharmaceuticals, Insider Trading, Stock Transaction, Lisa DeFrancesco, Restricted Stock Units, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.